36742201|t|Lipid profiles in the cerebrospinal fluid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson's disease.
36742201|a|Background: Parkinson's disease (PD) is a progressive neurodegenerative disease with characteristic pathological abnormalities, including the loss of dopaminergic (DA) neurons, a dopamine-depleted striatum, and microglial activation. Lipid accumulation exhibits a close relationship with these pathologies in PD. Methods: Here, 6-hydroxydopamine (6-OHDA) was used to construct a rat model of PD, and the lipid profile in cerebrospinal fluid (CSF) obtained from model rats was analyzed using lipidomic approaches. Results: Establishment of this PD model was confirmed by apomorphine-induced rotation behaviors, loss of DA neurons, depletion of dopamine in the striatum, and microglial activation after 6-OHDA-induced lesion generation. Unsupervised and supervised methods were employed for lipid analysis. A total of 172 lipid species were identified in CSF and subsequently classified into 18 lipid families. Lipid families, including eicosanoids, triglyceride (TG), cholesterol ester (CE), and free fatty acid (FFA), and 11 lipid species exhibited significantly altered profiles 2 weeks after 6-OHDA administration, and significant changes in eicosanoids, TG, CE, CAR, and three lipid species were noted 5 weeks after 6-OHDA administration. During the period of 6-OHDA-induced lesion formation, the lipid families and species showed concentration fluctuations related to the recovery of behavior and nigrostriatal abnormalities. Correlation analysis showed that the levels of eicosanoids, CE, TG families, and TG (16:0_20:0_18:1) exhibited positive relationships with apomorphine-induced rotation behaviors and negative relationships with tyrosine hydroxylase (TH) expression in the midbrain. Conclusion: These results revealed that non-progressive nigrostriatal degeneration induced by 6-OHDA promotes the expression of an impairment-related lipidomic signature in CSF, and the level of eicosanoids, CE, TG families, and TG (16:0_20:0_18:1) in CSF may reveal pathological changes in the midbrain after 6-OHDA insult.
36742201	0	5	Lipid	Chemical	MESH:D008055
36742201	45	49	rats	Species	10116
36742201	55	72	6-hydroxydopamine	Chemical	MESH:D016627
36742201	103	122	Parkinson's disease	Disease	MESH:D010300
36742201	136	155	Parkinson's disease	Disease	MESH:D010300
36742201	157	159	PD	Disease	MESH:D010300
36742201	178	203	neurodegenerative disease	Disease	MESH:D019636
36742201	274	286	dopaminergic	Chemical	MESH:D004298
36742201	288	290	DA	Chemical	MESH:D004298
36742201	303	311	dopamine	Chemical	MESH:D004298
36742201	358	363	Lipid	Chemical	MESH:D008055
36742201	433	435	PD	Disease	MESH:D010300
36742201	452	469	6-hydroxydopamine	Chemical	MESH:D016627
36742201	471	477	6-OHDA	Chemical	MESH:D016627
36742201	503	506	rat	Species	10116
36742201	516	518	PD	Disease	MESH:D010300
36742201	528	533	lipid	Chemical	MESH:D008055
36742201	591	595	rats	Species	10116
36742201	668	670	PD	Disease	MESH:D010300
36742201	694	705	apomorphine	Chemical	MESH:D001058
36742201	714	732	rotation behaviors	Disease	MESH:D009759
36742201	742	744	DA	Chemical	MESH:D004298
36742201	767	775	dopamine	Chemical	MESH:D004298
36742201	825	831	6-OHDA	Chemical	MESH:D016627
36742201	913	918	lipid	Chemical	MESH:D008055
36742201	944	949	lipid	Chemical	MESH:D008055
36742201	1017	1022	lipid	Chemical	MESH:D008055
36742201	1033	1038	Lipid	Chemical	MESH:D008055
36742201	1059	1070	eicosanoids	Chemical	MESH:D015777
36742201	1072	1084	triglyceride	Chemical	MESH:D014280
36742201	1086	1088	TG	Chemical	MESH:D014280
36742201	1091	1108	cholesterol ester	Chemical	MESH:D002788
36742201	1119	1134	free fatty acid	Chemical	MESH:D005230
36742201	1136	1139	FFA	Chemical	MESH:D005230
36742201	1149	1154	lipid	Chemical	MESH:D008055
36742201	1218	1224	6-OHDA	Chemical	MESH:D016627
36742201	1268	1279	eicosanoids	Chemical	MESH:D015777
36742201	1281	1283	TG	Chemical	MESH:D014280
36742201	1304	1309	lipid	Chemical	MESH:D008055
36742201	1343	1349	6-OHDA	Chemical	MESH:D016627
36742201	1387	1393	6-OHDA	Chemical	MESH:D016627
36742201	1424	1429	lipid	Chemical	MESH:D008055
36742201	1525	1552	nigrostriatal abnormalities	Disease	MESH:D000014
36742201	1601	1612	eicosanoids	Chemical	MESH:D015777
36742201	1618	1620	TG	Chemical	MESH:D014280
36742201	1635	1637	TG	Chemical	MESH:D014280
36742201	1693	1704	apomorphine	Chemical	MESH:D001058
36742201	1713	1731	rotation behaviors	Disease	MESH:D009759
36742201	1764	1784	tyrosine hydroxylase	Gene	25085
36742201	1786	1788	TH	Gene	25085
36742201	1874	1900	nigrostriatal degeneration	Disease	MESH:D009410
36742201	1912	1918	6-OHDA	Chemical	MESH:D016627
36742201	2013	2024	eicosanoids	Chemical	MESH:D015777
36742201	2030	2032	TG	Chemical	MESH:D014280
36742201	2047	2049	TG	Chemical	MESH:D014280
36742201	2128	2134	6-OHDA	Chemical	MESH:D016627
36742201	Association	MESH:D015777	MESH:D016627
36742201	Positive_Correlation	MESH:D016627	MESH:D009410
36742201	Negative_Correlation	MESH:D015777	25085
36742201	Association	MESH:D014280	MESH:D016627
36742201	Positive_Correlation	MESH:D001058	MESH:D014280
36742201	Association	MESH:D001058	MESH:D015777
36742201	Positive_Correlation	MESH:D001058	MESH:D009759
36742201	Negative_Correlation	MESH:D004298	MESH:D010300
36742201	Association	MESH:D002788	MESH:D016627
36742201	Positive_Correlation	MESH:D015777	MESH:D009759
36742201	Association	MESH:D008055	MESH:D000014
36742201	Positive_Correlation	MESH:D014280	MESH:D009759
36742201	Negative_Correlation	MESH:D014280	25085
36742201	Association	MESH:D008055	MESH:D010300
36742201	Association	MESH:D016627	MESH:D009759
36742201	Negative_Correlation	MESH:D016627	MESH:D000014
36742201	Negative_Correlation	MESH:D016627	MESH:D010300
36742201	Association	MESH:D005230	MESH:D016627
36742201	Association	MESH:D008055	MESH:D016627

